Abscess global clinical trials review, h1, 2017

HealthcareHealthcare
Abscess Global Clinical Trials
Review, H1, 2017
Reference Code: GDHC4063CTIDB
Publication Date: FEB 2017

Abscess Global Clinical Trials Review, H1, 2017
Publication Date: FEB 2017 Healthcare
© GlobalData 2017. This product is licensed and is not to be photocopied. Page 2
Table of Contents
Table of Contents............................................................................................................................................................................2
List of Tables...............................................................................................................................................................................3
List of Figures..............................................................................................................................................................................3
Report Guidance .............................................................................................................................................................................4
Clinical Trials by Region.................................................................................................................................................................5
Clinical Trials and Average Enrollment by Country...............................................................................................................6
Top Five Countries Contributing to Clinical Trials in Asia-Pacific...................................................................................8
Top Five Countries Contributing to Clinical Trials in Europe ..........................................................................................9
Top Countries Contributing to Clinical Trials in North America.....................................................................................10
Top Five Countries Contributing to Clinical Trials in Middle East and Africa...............................................................11
Top Five Countries Contributing to Clinical Trials in Central and South America...................................................... 12
Clinical Trials by G7 Countries: Proportion of Abscess to Infectious Disease Clinical Trials ............................................ 13
Clinical Trials by Phase in G7 Countries ...................................................................................................................................14
Clinical Trials in G7 Countries by Trial Status .......................................................................................................................... 15
Clinical Trials by E7 Countries: Proportion of Abscess to Infectious Disease Clinical Trials............................................. 16
Clinical Trials by Phase in E7 Countries.................................................................................................................................... 17
Clinical Trials in E7 Countries by Trial Status...........................................................................................................................18
Clinical Trials by Phase................................................................................................................................................................ 19
In Progress Trials by Phase................................................................................................................................................... 20
Clinical Trials by Trial Status ....................................................................................................................................................... 21
Clinical Trials by End Point Status..............................................................................................................................................22
Subjects Recruited Over a Period of Time............................................................................................................................... 23
Clinical Trials by Sponsor Type.................................................................................................................................................. 24
Prominent Sponsors .....................................................................................................................................................................25
Top Companies Participating in Abscess Therapeutics Clinical Trials............................................................................ 26
Prominent Drugs ...........................................................................................................................................................................27
Clinical Trial Profile Snapshots .................................................................................................................................................. 28
Appendix.........................................................................................................................................................................................92
Abbreviations ............................................................................................................................................................................92
Definitions..................................................................................................................................................................................92
Research Methodology........................................................................................................................................................... 93
Secondary Research .............................................................................................................................................................. 93
About GlobalData .................................................................................................................................................................... 94
Disclaimer................................................................................................................................................................................. 94
Source............................................................................................................................................................................................ 94

List of Tables
Abscess Therapeutics, Global, Clinical Trials by Region, 2017* .............................................................................................5
Abscess Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* .....................................6
Abscess Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* ........................................................... 7
Abscess Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* ....................................................................8
Abscess Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* ............................................................................9
Abscess Therapeutics Clinical Trials, North America, Top Countries, 2017* ......................................................................10
Abscess Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* ................................................11
Abscess Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* ....................................... 12
Proportion of Abscess to Infectious Disease Clinical Trials, G7 Countries (%), 2017* ...................................................... 13
Abscess Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*.................................................................................14
Abscess Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*........................................................................ 15
Proportion of Abscess to Infectious Disease Clinical Trials, E7 Countries (%), 2017*....................................................... 16
Abscess Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* ................................................................................. 17
Abscess Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* ........................................................................18
Abscess Therapeutics, Global, Clinical Trials by Phase, 2017*............................................................................................. 19
Abscess Therapeutics, Global, Clinical Trials In Progress by Phase 2017* ....................................................................... 20
Abscess Therapeutics, Global, Clinical Trials by Trial Status, 2017*.................................................................................... 21
Abscess Therapeutics Clinical Trials, Global, by End Point Status, 2017* ..........................................................................22
Abscess Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016....................................... 23
Abscess Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*................................................................. 24
Abscess Therapeutics Clinical Trials, Global, Key Sponsors, 2017* ....................................................................................25
Abscess Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* .............................................................. 26
Abscess Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* .................................27
List of Figures
Abscess Therapeutics, Global, Clinical Trials by Region (%), 2017*......................................................................................5
Abscess Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* .....................................6
Abscess Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* ........................................................... 7
Abscess Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*.............................................................8
Abscess Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*.....................................................................9
Abscess Therapeutics Clinical Trials, North America, Top Countries (%), 2017* ...............................................................10
Abscess Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* .........................................11
Abscess Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* ................................ 12
Proportion of Abscess to Infectious Disease Clinical Trials, G7 Countries (%), 2017* ...................................................... 13
Abscess Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*.................................................................................14
Abscess Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*........................................................................ 15
Proportion of Abscess to Infectious Disease Clinical Trials, E7 Countries (%), 2017*....................................................... 16
Abscess Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* ................................................................................. 17
Abscess Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* ........................................................................18
Abscess Therapeutics, Global, Clinical Trials by Phase (%), 2017* ..................................................................................... 19
Abscess Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* ...................................................................... 20
Abscess Therapeutics, Global, Clinical Trials by Trial Status, 2017*.................................................................................... 21
Abscess Therapeutics Clinical Trials, Global, by End Point Status, 2017* .........................................................................22
Abscess Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016....................................... 23
Abscess Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* ......................................................... 24
Abscess Therapeutics Clinical Trials, Global, Key Sponsors, 2017* ...................................................................................25
Abscess Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* ............................................................. 26
Abscess Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* ................................27
GlobalData Methodology............................................................................................................................................................. 93

Report Guidance
Abscess Global Clinical Trials Review, H1, 2017 outlines clinical trials in Abscess. The prominent features of this
report are -
1. Comprehensive data related to Abscess clinical trials by region, country, phase, and recruitment status
2. Clinical trials conducted by key Companies and Institutes. The selection of the sponsors is based on the
total number of Abscess clinical trials conducted
3. Prominent drugs are provided based on number of ongoing clinical trials
4. The trials compiled in this report are from clinical trial registries, conferences, journals etc

Clinical Trials by Region
I
Abscess Therapeutics, Global, Clinical Trials by Region (%), 2017*
Source: GlobalData’s Pharma Intelligence Center Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2017
2017 trials are taken as of February 2017
Abscess Therapeutics, Global, Clinical Trials by Region, 2017*
World Zones Number of Clinical Trials
North America
Asia-Pacific
Europe
Middle East and Africa
South and Central America
Locations Not Specified
Total

Clinical Trials by G7 Countries: Proportion of Abscess to Infectious Disease
Clinical Trials
Proportion of Abscess to Infectious Disease Clinical Trials, G7 Countries (%), 2017*
Proportion of Abscess to Infectious Disease Clinical Trials, G7 Countries (%), 2017*
Country Name Number of Clinical Trials on
Infectious Disease
Number of Clinical Trials On
Abscess
Proportion of Abscess to
Infectious Disease Clinical Trials
(%)
United States
Germany
United Kingdom
Japan
Canada
France
Italy

Clinical Trials by E7 Countries: Proportion of Abscess to Infectious Disease
Clinical Trials
Proportion of Abscess to Infectious Disease Clinical Trials, E7 Countries (%), 2017*
Proportion of Abscess to Infectious Disease Clinical Trials, E7 Countries (%), 2017*
Country Name Number of Clinical Trials on
Infectious Disease
Number of Clinical Trials On
Abscess
Proportion of Abscess to
Infectious Disease Clinical Trials
(%)
China
India
Brazil
Russia
Mexico
Turkey
Indonesia

Clinical Trial Profile Snapshots
Note:
1. The trials below have been collected from 70+ registries, conferences, company websites,
journals, etc.
2. All the trials get updated based on the press releases, SEC filings, Investor presentations,
conferences, registry updates, etc.
3. GDCT ID is the unique ID of GlobalData’s Pharma Intelligence Center clinical trial database
4. Drug/Molecule refers to Primary Intervention only.
5. All the trials included are unique trials.
Clinical Trial profile. 1
Trial Title
Official Title
Trial Identifier
Secondary ID(s)
Therapy Area
Indication(s)
Trial Status
Trial Phase
Study Type
Drug(s)/Molecule(s)
Sponsor(s)
Estimated Start Date
Estimated Completion
Date
# of Subjects Planned
# of Investigator(s)

Trial Title
Official Title
Trial Identifier
Secondary ID(s)
Therapy Area
Indication(s)
Trial Status
Trial Phase
Study Type
Drug(s)/Molecule(s)
Sponsor(s)
Collaborator(s)
Date
# of Subjects Planned
# of Location(s)
# of Investigator(s)
Mechanism of Action
Target
Trial Title
Official Title
Trial Identifier
Secondary ID(s)
Therapy Area
Indication(s)
Trial Status
Trial Phase
Study Type
Drug(s)/Molecule(s)
Sponsor(s)
Date
Mechanism of Action
Target

Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2017
Appendix
Abbreviations
BRIC: Brazil, Russia, India and China
Definitions
PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans,
the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include
healthy participants and/or patients.
PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a
particular indication or indications in patients with the disease or condition under study and to determine the
common short-term side effects and risks.
PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting
effectiveness of the drug has been obtained, and were intended to gather additional information to evaluate the
overall benefit-risk relationship of the drug and provide an adequate basis for physician labeling.
PHASE IV TRIALS: Post-marketing studies to delineate additional information including the drug's risks,
benefits, and optimal use.
Other: Studies where phase is not mentioned.
TRIAL STATUS: Indicates the current stage of a trial, whether it is planned, ongoing, or completed. Possible
values include:
Trial in Progress: This is inclusive of;
Planned: participants were not yet being recruited or enrolled
Recruiting: participants were currently being recruited and enrolled
Enrolling by invitation: participants were being (or will be) selected from a predetermined population
Active, not recruiting: study is ongoing (i.e., patients were being treated or examined), but enrollment
has completed
Completed: the study has concluded normally; participants were no longer being examined or treated
(i.e., last patient's last visit has occurred)
Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume
Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants
were no longer being examined or treated
Withdrawn: study halted prematurely, prior to enrollment of first participant
SUBJECTS RECRUITED: The number of patients so enrolled for the trial in concern, to be analyzed.
UNACCOMPLISHED TRIALS: The category comprising of the terminated, withdrawn and suspended trials.

Research Methodology
GlobalData dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in
marketing, market research and consulting in the pharmaceutical industry with advanced statistical expertise.
GlobalData adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Society
of Competitive Intelligence Professionals (www.scip.org).
All GlobalData databases were continuously updated and revised. The following research methodology is
followed for all databases and reports.
GlobalData Methodology
Source: GlobalData
Secondary Research
The research process begins with exhaustive secondary research on internal and external sources being carried
out to source qualitative and quantitative information relating to each market.
The secondary research sources that were typically referred to include, but were not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC Filings;
Industry trade journals, scientific journals and other technical literature;
Internal and external proprietary databases;
Relevant patent and regulatory databases;
National government documents, statistical databases and market reports;
Procedure registries; and
News articles, press releases and web-casts specific to the companies operating in the market.

About GlobalData
We hope that the data and analysis in this brief will help you make informed and imaginative business decisions.
If you have further requirements, GlobalData consulting team may be able to help you. GlobalData offers Tailor
made analytical and advisory services to drive your key strategic decisions.
Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any
means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the
publisher, GlobalData.
Source
http://clinicaltrials.gov/
http://www.pharmaetrack.com/
https://www.goldbamboo.com/pictures-t1192.html
http://www.trialscentral.org/
http://www.thefreelibrary.com/
http://dailymed.nlm.nih.gov/dailymed/about.cfm
http://www.controlled-trials.com/isrctn/search.html
http://www.anzctr.org.au/trialSearch.aspx
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=input&language=E

Abscess global clinical trials review, h1, 2017

Recommended

Recommended

More Related Content

Similar to Abscess global clinical trials review, h1, 2017

Similar to Abscess global clinical trials review, h1, 2017 (20)

More from Market Research Report Store

More from Market Research Report Store (12)

Recently uploaded

Recently uploaded (20)

Abscess global clinical trials review, h1, 2017